2 results
Approved WMOCompleted
The primary objective is to assess whether RD added to usual care compared to usual care alone reduces BP (24-h or average day-time SBP as determined with the use of ambulatory BP monitoring (ABPM)) in subjects with an average mean day-time SBP of…
Approved WMOCompleted
To provide continued bevacizumab therapy as single agent or in combination with an anti-cancer drug to patients with cancer, who were previously enrolled in a F. Hoffmann-La Roche (Roche)/ Genentech sponsored bevacizumab study (i.e. the Parent, P-…